Evidence map›Paper›PMID 41098218›Full record

ArticleEJIFCC2025

A Case of Myelodysplastic Syndrome-Induced Acquired Sideroblastic Anemia.

Bremansu Osa-Andrews, John O Ogunbileje, Neil Harris, Tung Wynn

Abstract readCase Reports
In one paragraph

Article in EJIFCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bremansu Osa-AndrewsUniversity of Florida, College of Medicine, Gainesville, USA.
John O OgunbilejeIndiana University; School of Medicine, Indianapolis, USA.
Neil HarrisUniversity of Florida, College of Medicine, Gainesville, USA.
Tung WynnUniversity of Florida, College of Medicine, Gainesville, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematological disorders are frequently encountered at the doctor's office and in the emergency room. Sideroblastic anemia, a rare hematological malady, is characterized by ring sideroblasts in the red blood cells due to accumulation of poorly transported and underutilized iron. Unlike primary sideroblastic anemia which can be conclusively diagnosed through genetic testing, the more common secondary form of the disease requires intricate cascading of several preliminary and confirmatory laboratory testing to determine the accurate etiology and provide the appropriate management regimen. The scope of laboratory medicine is broadening; clinical chemists and other laboratorians are tasked with directing broader clinical pathology sections, including Core lab hematology. Understanding the testing dynamics, diagnostic criteria and management of hematological diseases is fundamental to attaining success in consulting with providers to manage diseases such as sideroblastic anemia. Via a relevant case study, we explore the etiology, workup, symptoms, and treatment of myelodysplastic syndrome-induced sideroblastic anemia.

Indexed as

anemiahematologicalmyelodysplasticSideroblastic

Identifiers

PMID41098218
PMCPMC12519671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.